Holen Sie sich die Stockscreener-App
9.97
3.10%
0.30
Handel nachbörslich:
9.78
-0.19
-1.91%
Schlusskurs vom Vortag:
$9.67
Offen:
$9.6
24-Stunden-Volumen:
647.38K
Relative Volume:
0.55
Marktkapitalisierung:
$465.62M
Einnahmen:
$20.72M
Nettoeinkommen (Verlust:
$-100.84M
KGV:
-3.7481
EPS:
-2.66
Netto-Cashflow:
$-78.56M
1W Leistung:
+19.83%
1M Leistung:
+46.40%
6M Leistung:
+258.63%
1J Leistung:
+10.41%
1-Tages-Spanne:
$9.40
$10.06
1-Wochen-Bereich:
$8.30
$10.06
52-Wochen-Spanne:
$2.235
$10.06
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Vergleichen Sie FDMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.97 | 415.65M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
Retinitis Pigmentosa Market to Expand Significantly by 2034, States DelveInsight Report | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc - The Globe and Mail
4D Molecular Therapeutics to Participate in Chardan’s 9th Annual Genetic Medicines Conference Panel Discussions - Quiver Quantitative
Can momentum traders help lift 4D Molecular Therapeutics Inc.Quarterly Investment Review & Daily Stock Trend Reports - newser.com
4D Molecular Therapeutics, Inc. announced that it expects to receive $11 million in funding from Cystic Fibrosis Foundation - MarketScreener
Will 4D Molecular Therapeutics Inc. outperform the marketJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study - MarketScreener
Published on: 2025-10-13 08:38:02 - newser.com
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTrade Ideas & Precise Buy Zone Tips - newser.com
Is it too late to sell 4D Molecular Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
4D Molecular (FDMT) Gains $11M Support for Cystic Fibrosis Treat - GuruFocus
Is it time to cut losses on 4D Molecular Therapeutics Inc.Trade Signal Summary & Risk Managed Investment Strategies - newser.com
4D Molecular Therapeutics, Inc. Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation - MarketScreener
When is the best time to exit 4D Molecular Therapeutics Inc.Rate Hike & Risk Managed Investment Entry Signals - newser.com
Momentum divergence signals in 4D Molecular Therapeutics Inc. chart2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Will 4D Molecular Therapeutics Inc. see short term momentumJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
4D Molecular Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Access Powerful Market Insights - earlytimes.in
Real time alert setup for 4D Molecular Therapeutics Inc. performancePortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
What drives 4D Molecular Therapeutics Inc stock priceTrade Execution Strategies & Free Stock Chart Pattern Guides - earlytimes.in
Statistical indicators supporting 4D Molecular Therapeutics Inc.’s strength2025 Valuation Update & Weekly High Return Opportunities - newser.com
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance
How 4D Molecular Therapeutics Inc. stock responds to policy changesJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
What MACD signals say about 4D Molecular Therapeutics Inc.2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
What the charts say about 4D Molecular Therapeutics Inc. todayProduct Launch & Accurate Buy Signal Alerts - newser.com
4D Molecular Therapeutics says on Sept 30, appointed Ashoo Gupta as principal financial officerSEC filing - MarketScreener
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT) - Seeking Alpha
What analysts say about 4D Molecular Therapeutics Inc stockMarket Insider Reports & Free Explosive Wealth Accumulation - earlytimes.in
Is 4D Molecular Therapeutics Inc. stock reversal real or fakeWeekly Stock Summary & Consistent Growth Equity Picks - newser.com
News impact scoring models applied to 4D Molecular Therapeutics Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 By Investing.com - Investing.com Canada
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 - Investing.com India
4D Molecular Therapeutics Inc. stock daily chart insightsWeekly Trend Report & Verified Technical Trade Signals - newser.com
Is 4D Molecular Therapeutics Inc. stock bottoming outStop Loss & Accurate Entry/Exit Alerts - newser.com
Custom strategy builders for tracking 4D Molecular Therapeutics Inc.2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):